reports

Nexteer Reports 2025 Year End Results

Continues Above-Market Growth with Expanding MarginsAUBURN HILLS, Mich., March 24, 2026 /PRNewswire/ -- Nexteer Automotive (HK 1316) today reported financial…

3 hours ago

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

March 20, 2026 16:30 ET  | Source: Zevra Therapeutics BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS:…

3 days ago

GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth

Group PerformanceRevenue: US$959.5 million, +61.4% year-on-yearGross profit: US$553.2 million, +103.3% year-on-yearAdjusted net profit: US$230.3 million, +285.0% year-on-yearBusiness Units' PerformanceGenScript Life…

4 days ago

Crescel Reports Positive Randomized Controlled Trial Results for Biobotanical Skin Renewal Cream in Rosacea

Study Shows Greater Clinical Improvement vs. Metronidazole-Based Standard of Care with Favorable TolerabilityMIAMI BEACH, Fla., March 20, 2026 /PRNewswire/ -- Crescel LLC,…

5 days ago

Cango Inc. Reports Fourth Quarter and Full Year 2025 Unaudited Financial Results

DALLAS, March 16, 2026 /PRNewswire/ -- Cango Inc. (NYSE: CANG), a leading Bitcoin miner leveraging its global operations to develop an…

6 days ago

VitalHub Reports Fourth Quarter 2025 Results

Annual Recurring Revenue (“ARR”)⁽¹⁾ up 35% YoY to $96.1 millionTotal Revenue up 52% YoY to $31.4 millionAdjusted EBITDA⁽¹⁾ up 47%…

6 days ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

March 12, 2026 21:03 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

2 weeks ago

Hybrid Software Group PLC reports 2025 results with 17% increase in adjusted operating profit and 252% increase in net cash

PRESS RELEASE – REGULATED INFORMATION HYBRID SOFTWARE GROUP PLC REPORTS 2025 RESULTS WITH 17% INCREASE IN ADJUSTED OPERATING PROFIT AND…

2 weeks ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Presented positive updated data from the ALLOHA™ Phase 1 heme trial at 67th American Society of Hematology (ASH) Annual Meeting…

3 weeks ago